ECSP20023626A - Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 - Google Patents

Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Info

Publication number
ECSP20023626A
ECSP20023626A ECSENADI202023626A ECDI202023626A ECSP20023626A EC SP20023626 A ECSP20023626 A EC SP20023626A EC SENADI202023626 A ECSENADI202023626 A EC SENADI202023626A EC DI202023626 A ECDI202023626 A EC DI202023626A EC SP20023626 A ECSP20023626 A EC SP20023626A
Authority
EC
Ecuador
Prior art keywords
pyrimidine
compounds
pirazolo
pirrolo
novelty
Prior art date
Application number
ECSENADI202023626A
Other languages
English (en)
Inventor
Holger Siebeneicher
Oliver Fischer
Shelley Parrott
Marcus Koppitz
Adam Davenport
Ursinyova Nina Connelly
Nico Bräuer
Robert Townsend
Elisabeth Pook
Andrea Rotgeri
James Carr
Jens Nagel
Roland Neuhaus
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of ECSP20023626A publication Critical patent/ECSP20023626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención cubre compuestos de pirazolo-pirrolo-pirimidin-diona sustituidos (PPPD) de la fórmula general (I): en la cual R1, R2 y R3 son como se los define en esta memoria, métodos de preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades neurogénicas, como agente único en combinación con otros principios activos.
ECSENADI202023626A 2017-10-27 2020-04-24 Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 ECSP20023626A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27

Publications (1)

Publication Number Publication Date
ECSP20023626A true ECSP20023626A (es) 2020-06-30

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202023626A ECSP20023626A (es) 2017-10-27 2020-04-24 Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Country Status (26)

Country Link
US (1) US11319324B2 (es)
EP (1) EP3700907B1 (es)
JP (1) JP7250011B2 (es)
KR (1) KR20200078567A (es)
CN (1) CN111527090B (es)
AU (1) AU2018354777A1 (es)
BR (1) BR112020008122B1 (es)
CA (1) CA3080249A1 (es)
CL (1) CL2020001107A1 (es)
CO (1) CO2020005065A2 (es)
CR (1) CR20200174A (es)
CU (1) CU20200038A7 (es)
DK (1) DK3700907T3 (es)
DO (1) DOP2020000100A (es)
EA (1) EA202091003A1 (es)
EC (1) ECSP20023626A (es)
ES (1) ES2914377T3 (es)
IL (1) IL274036A (es)
JO (1) JOP20200100A1 (es)
MA (1) MA50439A (es)
MX (1) MX2020004981A (es)
NI (1) NI202000031A (es)
PE (1) PE20200932A1 (es)
PH (1) PH12020550494A1 (es)
SG (1) SG11202003662XA (es)
WO (1) WO2019081343A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
TWI886184B (zh) * 2019-12-10 2025-06-11 大陸商上海翰森生物醫藥科技有限公司 含吡唑多環類衍生物抑制劑、其製備方法和應用
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
BR112023025543A2 (pt) * 2021-06-09 2024-02-27 Jiangsu Hansoh Pharmaceutical Group Co Ltd Forma de sal e cristal de derivado policíclico contendo pirazol, e método de preparação do mesmo e uso do mesmo
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
AR132698A1 (es) * 2023-05-17 2025-07-23 Insilico Medicine Ip Ltd DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
WO2025137640A1 (en) * 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425541A1 (en) * 1988-07-21 1991-05-08 The Upjohn Company Pyrazolo-azolo-pyrimidine-diones
WO1997011946A1 (en) * 1995-09-28 1997-04-03 Otsuka Pharmaceutical Factory, Inc. Analgesics
PL355148A1 (en) 1999-11-05 2004-04-05 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
AU2007260851B2 (en) 2006-06-23 2013-01-17 Incyte Corporation Purinone derivatives as HM74a agonists
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
BR112014003296A2 (pt) * 2011-08-12 2017-03-14 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
WO2013185124A1 (en) 2012-06-08 2013-12-12 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
US9346812B2 (en) * 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CR20200174A (es) 2020-06-26
PH12020550494A1 (en) 2021-01-11
SG11202003662XA (en) 2020-05-28
US20210317128A1 (en) 2021-10-14
CN111527090A (zh) 2020-08-11
JP2021500380A (ja) 2021-01-07
KR20200078567A (ko) 2020-07-01
EP3700907B1 (en) 2022-03-09
MX2020004981A (es) 2020-08-24
EP3700907A1 (en) 2020-09-02
CU20200038A7 (es) 2021-03-11
DOP2020000100A (es) 2020-09-15
MA50439A (fr) 2021-05-19
US11319324B2 (en) 2022-05-03
BR112020008122A2 (pt) 2020-11-03
NI202000031A (es) 2020-08-28
PE20200932A1 (es) 2020-09-17
JOP20200100A1 (ar) 2020-05-06
CO2020005065A2 (es) 2020-05-29
WO2019081343A1 (en) 2019-05-02
AU2018354777A1 (en) 2020-04-16
CA3080249A1 (en) 2019-05-02
DK3700907T3 (da) 2022-05-30
CL2020001107A1 (es) 2020-10-23
BR112020008122B1 (pt) 2022-11-01
ES2914377T3 (es) 2022-06-10
JP7250011B2 (ja) 2023-03-31
EA202091003A1 (ru) 2020-09-11
IL274036A (en) 2020-06-30
CN111527090B (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
DOP2020000023A (es) Nuevos derivados de quinolina
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO2019014484A2 (es) Nuevos derivados de azaquinolina
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
ECSP17073965A (es) Derivados de ciclohexano sustituido con amido
CO2020001242A2 (es) Dihidrooxadiazinonas
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
DOP2016000253A (es) Nuevos compuestos
CL2020002891A1 (es) Nuevos derivados de quinolina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY37250A (es) Derivados macrocíclicos de indol
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX2017008373A (es) Compuestos, composiciones y metodos.
UY37032A (es) Compuestos de heteroarilbenzimidazol